Bluebird Bio's (BLUE) Abecma Becomes the First BCMA Targeting CAR-T Therapy to Reach the Market - Stifel

Go back to Bluebird Bio's (BLUE) Abecma Becomes the First BCMA Targeting CAR-T Therapy to Reach the Market - Stifel
BLUEBIRD BIO (NASDAQ: BLUE) Delayed: 29.67 --0 (-0%)
Previous Close $29.67    52 Week High $95.28 
Open $29.67    52 Week Low $35.37 
Day High $29.67    P/E N/A 
Day Low $29.67    EPS $-1.81 
Volume 300